Anti-HSP90 alpha/beta Purified

*Reiter K, Aguilar PP, Wetter V, Steppert P, Tover A, Jungbauer A: Separation of virus-like particles and extracellular vesicles by flow-through and heparin affinity chromatography. J Chromatogr A. 2019 Mar 15;1588:77-84, URL: https://pubmed.ncbi.nlm.nih.gov/30616980/

*Millson SH, Truman AW, Rácz A, Hu B, Panaretou B, Nuttall J, Mollapour M, Söti C, Piper PW: Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol. FEBS J. 2007 Sep;274 (17) :4453-63., URL: https://www.ncbi.nlm.nih.gov/pubmed/17681020?ordin, *Pearl LH, Prodromou C, Workman P: The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J. 2008 Mar 15;410 (3) :439-53., URL: https://www.ncbi.nlm.nih.gov/pubmed/18290764?ordin, *Hooven TA, Yamamoto Y, Jeffery WR: Blind cavefish and heat shock protein chaperones: a novel role for hsp90alpha in lens apoptosis. Int J Dev Biol. 2004;48 (8-9) :731-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/15558465?ordin, *Scheibel T, Buchner J: The Hsp90 complex--a super-chaperone machine as a novel drug target. Biochem Pharmacol. 1998 Sep 15;56 (6) :675-82., URL: https://www.ncbi.nlm.nih.gov/pubmed/9751071?ordina, *Pratt WB: The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med. 1998 Apr;217 (4) :420-34., URL: https://www.ncbi.nlm.nih.gov/pubmed/9521088?ordina